Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS

Background: Low-doses of bone modifying agents (LD-BMAs) compared to those used to treat bone metastases are used in breast or prostate cancer patients on adjuvant endocrine therapy to prevent Cancer Treatment Induced Bone Loss (CTIBL). Their use is associated with an increased risk of developing Me...

Description complète

Détails bibliographiques

Auteurs principaux:	Francesco Bertoldo, Cristina Eller-Vainicher, Vittorio Fusco, Rodolfo Mauceri, Jessica Pepe, Alberto Bedogni, Andrea Palermo, Umberto Romeo, Giuseppe Guglielmi, Giuseppina Campisi
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2025-02-01
Collection:	Journal of Bone Oncology
Sujets:	Osteonecrosis of the jaw Breast cancer Prostate cancer CTIBL Denosumab Bisphosphonate
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S2212137424001362
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!